“There have never been testosterone charged acquisition sprees.”
Given Axiron’s demise and the declining testosterone market in general, I think the T word would no longer even rate a mention in the Acrux office, let alone drive wayward acquisitions
One thing I would be curious to know, if anyone has some data or experience in this area, is the strike rate of success for products going from FDA dossier submission to market.
ACR Price at posting:
15.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
